Cantor Sees 'clear Strategic Rationale' Behind Vertex's Buy of Crinetics

Dow Jones07-07

Vertex Pharmaceuticals' roughly $10 billion purchase of Crinetics Pharmaceuticals provides another near-term launch narrative with Palsonify, a treatment for acromegaly, Cantor analysts say in a research note. It also offers a clinically compelling program with multi-blockbuster potential in atumelnant, a possible treatment for congenital adrenal hyperplasia and Cushing's Syndrome, the analysts add. "Together, these assets give Vertex a foothold in endocrinology--a fifth therapeutic area for the company," they write. "We see clear strategic rationale: addition of solid, innovative science, with atumelnant carrying relatively modest binary risk." Vertex shares are roughly flat in premarket trading Tuesday, while Crinetics shares double. (connor.hart@wsj.com)

(END) Dow Jones Newswires

July 07, 2026 09:19 ET (13:19 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment